PT2485593E - Associação - Google Patents

Associação Download PDF

Info

Publication number
PT2485593E
PT2485593E PT108227331T PT10822733T PT2485593E PT 2485593 E PT2485593 E PT 2485593E PT 108227331 T PT108227331 T PT 108227331T PT 10822733 T PT10822733 T PT 10822733T PT 2485593 E PT2485593 E PT 2485593E
Authority
PT
Portugal
Prior art keywords
combination
Prior art date
Application number
PT108227331T
Other languages
English (en)
Inventor
Melissa Dumble
Tona Gilmer
Rakesh Kumar
Sylvie Laquerre
Peter F Lebowitz
Shannon Renae Morris
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PT2485593E publication Critical patent/PT2485593E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT108227331T 2009-10-08 2010-10-08 Associação PT2485593E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24980309P 2009-10-08 2009-10-08

Publications (1)

Publication Number Publication Date
PT2485593E true PT2485593E (pt) 2015-04-28

Family

ID=43857162

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108227331T PT2485593E (pt) 2009-10-08 2010-10-08 Associação

Country Status (16)

Country Link
US (2) US8835450B2 (pt)
EP (1) EP2485593B1 (pt)
JP (1) JP2013507382A (pt)
KR (1) KR20120100978A (pt)
CN (1) CN102665418B (pt)
AU (1) AU2010303363B2 (pt)
BR (1) BR112012008271A2 (pt)
CA (1) CA2777085A1 (pt)
EA (1) EA022982B1 (pt)
ES (1) ES2532026T3 (pt)
IL (1) IL218999A (pt)
MX (1) MX2012004139A (pt)
PL (1) PL2485593T3 (pt)
PT (1) PT2485593E (pt)
WO (1) WO2011044414A1 (pt)
ZA (1) ZA201202494B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201347758A (zh) * 2012-04-24 2013-12-01 葛蘭素史克智慧財產(第二)有限公司 用於類固醇反應性皮膚病的治療方法
WO2014066202A1 (en) * 2012-10-22 2014-05-01 Glaxosmithkline Llc Combination
EP2908816A4 (en) * 2012-10-22 2016-06-15 Novartis Ag ASSOCIATION
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
NZ518032A (en) * 1999-11-22 2004-02-27 Smithkline Beecham Plc Substituted imidazole derivatives
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
RS50569B (sr) * 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
KR20080091369A (ko) * 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 b (pkb) 억제제로서 티아졸 화합물
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
EA022982B1 (ru) 2016-04-29
CA2777085A1 (en) 2011-04-14
IL218999A0 (en) 2012-06-28
AU2010303363B2 (en) 2013-09-05
JP2013507382A (ja) 2013-03-04
EP2485593A4 (en) 2013-02-13
BR112012008271A2 (pt) 2015-09-22
ES2532026T3 (es) 2015-03-23
WO2011044414A1 (en) 2011-04-14
US9402846B2 (en) 2016-08-02
IL218999A (en) 2015-08-31
CN102665418B (zh) 2014-10-29
PL2485593T3 (pl) 2015-06-30
ZA201202494B (en) 2012-12-27
AU2010303363A1 (en) 2012-04-26
EP2485593B1 (en) 2015-01-07
US8835450B2 (en) 2014-09-16
CN102665418A (zh) 2012-09-12
US20140350039A1 (en) 2014-11-27
EP2485593A1 (en) 2012-08-15
EA201270526A1 (ru) 2012-12-28
MX2012004139A (es) 2012-09-07
US20120196886A1 (en) 2012-08-02
KR20120100978A (ko) 2012-09-12

Similar Documents

Publication Publication Date Title
DK3023438T3 (en) Anti-gitr-antistoffer
ZA201202612B (en) Combination
EP2462514A4 (en) GREEN BOOKS
IL219103A0 (en) Combination
IL219786A0 (en) Combination
ZA201202494B (en) Combination
ZA201202173B (en) Combination
GB0903253D0 (en) Omnibrush
ZA201202495B (en) Combination
ZA201202258B (en) Combination
IL218801A0 (en) Combination
GB0900568D0 (en) Poymerisation
GB0906696D0 (en) Combination
GB0901391D0 (en) Combination
GB0921334D0 (en) Preferred combination
GB0902622D0 (en) Teresa-2
GB0903311D0 (en) Fedorak-a-lope
GB0905116D0 (en) IssueControl
GB0908190D0 (en) Platocards
GB0910083D0 (en) Locusafe
GB0910084D0 (en) Visiclip3
GB0912798D0 (en) 7Locusafe
GB0903745D0 (en) Cancertest
GB0911516D0 (en) 7Locusafe
GB0912393D0 (en) ChopperStopper